IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia
Lymphoma, Non-Hodgkin - Chronic Lymphocytic Leukemia
Conditions: official terms
Leukemia - Leukemia, Lymphocytic, Chronic, B-Cell - Leukemia, Lymphoid - Lymphoma - Lymphoma, Non-Hodgkin
Study Type
Study Phase
Phase 1
Study Design
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Name: IMGN529
Type: Drug
Overall Status
The purpose of this study is to test the safety and tolerability of IMGN529 in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL).
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

- Relapsed or refractory NHL including tumor types: Follicular lymphoma (FL), marginal zone lymphoma (MZL)/mucosa-associated lymphoid tissue (MALT), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL).

- Adequate organ function

- ECOG ≤ 2

- Recovered or stabilized from prior treatments.

Exclusion Criteria:

- Allogeneic stem cell transplantation

- Pregnant or lactating females

- Known central nervous system, meningeal or epidural disease including brain metastases
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Status: Recruiting
Contact: Brendan Toohey, MD - 617-632-2368 -
Memorial Sloan-Kettering Cancer Center
New York, New York, United States
Status: Recruiting
Contact: Rebecca Green - 646-449-1312 -
Ohio State University
Columbus, Ohio, United States
Status: Recruiting
Contact: Misty Flemming - 614-688-9498 -
Sarah Cannon Research Institute
Nashville, Tennessee, United States
Status: Recruiting
Contact: Katie Rice - 615-329-7274 -
San Antonio, Texas, United States
Status: Recruiting
Contact: Kathleen Cobb - 210-450-5893 -
Oncology Institute of Southern Switzerland
Bellinzona, Switzerland
Status: Recruiting
Contact: Sheila Gaggetta, MD - +41918118215 -
Start Date
January 2012
ImmunoGen, Inc.
ImmunoGen, Inc.
Record processing date processed this data on July 28, 2015 page